drugset
drugset / Trial / NCT03809039

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of MT-6345 in Healthy Subjects

NCT03809039 ↗

Phase 1 Terminated 52 enrolled Tanabe Pharma America, Inc.
RandomizedSequentialQuadruple-blindOther

Summary

The purpose of this study is to Investigate the Safety, Tolerability and Pharmacokinetics of MT-6345 in Healthy Subjects.

Timeline

Start
2019-01-15
Primary completion
2019-07-01
Completion
2020-07-01

Outcome

Outcome not reported

Stopped: “Preclinical finding”

Drugs

EvaluationDrugModalityDoseRoute
Subject MT-6345 Unknown — —

Indications

No indication recorded.